Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert D Knight

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Melanoma Research|September 23, 2010
Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapyWen-Jen Hwu, Robert D Knight, Madhavi Patnana, et al.
Aging|September 26, 2020
Muscle defects due to perturbed somite segmentation contribute to late adult scoliosisLaura Lleras-Forero, Elis Newham, Stefan Teufel, et al.
Cancer|September 4, 2009
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanomaJohn Glaspy, Michael B Atkins, Jon M Richards, et al.
Developmental Biology|September 10, 2017
Myotome adaptability confers developmental robustness to somitic myogenesis in response to fibre number alterationShukolpa D Roy, Victoria C Williams, Tapan G Pipalia, et al.
Journal of Anatomy|February 7, 2023
Enhancer trap lines with GFP driven by smad6b and frizzled1 regulatory sequences for the study of epithelial morphogenesis in the developing zebrafish inner earDavide Baldera, Sarah Baxendale, Nicholas J van Hateren, et al.
Optics Letters|April 1, 2017
Functional in vivo imaging using fluorescence lifetime light-sheet microscopyClaire A Mitchell, Simon P Poland, James Seyforth, et al.
Elife|November 15, 2016
Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophyLouise A Moyle, Eric Blanc, Oihane Jaka, et al.
Haematologica|May 13, 2010
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myelomaJean-Luc Harousseau, Meletios A Dimopoulos, Michael Wang, et al.
Blood|September 19, 2008
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposureMichael Wang, Meletios A Dimopoulos, Christine Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 29, 2011
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasoneJesús F San-Miguel, Meletios A Dimopoulos, Edward A Stadtmauer, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Melanoma Research|September 23, 2010
Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapyWen-Jen Hwu, Robert D Knight, Madhavi Patnana, et al.
Aging|September 26, 2020
Muscle defects due to perturbed somite segmentation contribute to late adult scoliosisLaura Lleras-Forero, Elis Newham, Stefan Teufel, et al.
Cancer|September 4, 2009
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanomaJohn Glaspy, Michael B Atkins, Jon M Richards, et al.
Developmental Biology|September 10, 2017
Myotome adaptability confers developmental robustness to somitic myogenesis in response to fibre number alterationShukolpa D Roy, Victoria C Williams, Tapan G Pipalia, et al.
Journal of Anatomy|February 7, 2023
Enhancer trap lines with GFP driven by smad6b and frizzled1 regulatory sequences for the study of epithelial morphogenesis in the developing zebrafish inner earDavide Baldera, Sarah Baxendale, Nicholas J van Hateren, et al.
Optics Letters|April 1, 2017
Functional in vivo imaging using fluorescence lifetime light-sheet microscopyClaire A Mitchell, Simon P Poland, James Seyforth, et al.
Elife|November 15, 2016
Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophyLouise A Moyle, Eric Blanc, Oihane Jaka, et al.
Haematologica|May 13, 2010
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myelomaJean-Luc Harousseau, Meletios A Dimopoulos, Michael Wang, et al.
Blood|September 19, 2008
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposureMichael Wang, Meletios A Dimopoulos, Christine Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 29, 2011
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasoneJesús F San-Miguel, Meletios A Dimopoulos, Edward A Stadtmauer, et al.
Pageof 5